HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
SOPH
SOPHiA GENETICS S.A.
SOPH lost money over the past year, so it has no meaningful PE right now. Analysts expect losses to shrink.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
SOPH Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Under pressure | |
| Weak | |
| Unavailable |
SOPH's revenue is currently healthy, but its profitability and cash flow are under pressure. There isn't enough data to rate its balance sheet.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
SOPH PE Valuation
SOPH has no meaningful PE right now: it lost money over the past year.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
SOPH Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| High |
SOPH has the edge over HIMS on the outlook, with more favorable earnings and profitability expectations.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has the edge over SOPH on earnings, with more consistent year-over-year improvement.
SOPH Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | -$1.15 | -$0.05 |
| Q1 2026 | -$1.18 | -$0.18 |
| Q4 2025 | -$1.17 | -$0.22 |
| Q3 2025 | -$1.12 | -$0.03 |
| Q2 2025 | -$1.10 | -$0.08 |
| Q1 2025 | -$1.00 | +$0.12 |
| Q4 2024 | -$0.95 | +$0.27 |
| Q3 2024 | -$1.09 | -$0.02 |
SOPH is still losing money, but less than at its worst: $1.15 per share over the past year, against $1.51 at its worst in late 2022.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over SOPH on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS has the edge over SOPH on profitability, with a higher operating margin.
SOPH Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $23.3M | +27% |
| Q1 2026 | $21.7M | +22% |
| Q4 2025 | $21.7M | +22% |
| Q3 2025 | $19.5M | +23% |
| Q2 2025 | $18.3M | +16% |
| Q1 2025 | $17.8M | +13% |
| Q4 2024 | $17.7M | +4% |
| Q3 2024 | $15.9M | -2.8% |
SOPH's revenue has grown year over year for seven quarters in a row: $23M last quarter, up 27% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -86% | +15 points |
| Q1 2026 | -80% | +11 points |
| Q4 2025 | -83% | +15 points |
| Q3 2025 | -92% | +5.1 points |
| Q2 2025 | -101% | -6.4 points |
| Q1 2025 | -90% | +29 points |
| Q4 2024 | -98% | +13 points |
| Q3 2024 | -97% | +4.6 points |
SOPH's operating margin was −86% last quarter, up 15 points from the same quarter a year ago.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over SOPH on cash generation, producing positive trailing cash flow while its opponent burns cash.
SOPH Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$10.4M | -$199K |
| Q1 2026 | -$17.1M | -$4.8M |
| Q4 2025 | -$9.3M | +$3.3M |
| Q3 2025 | -$8.9M | +$581K |
| Q2 2025 | -$10.2M | +$2.2M |
| Q1 2025 | -$12.2M | +$4.4M |
| Q4 2024 | -$12.5M | +$1M |
| Q3 2024 | -$9.5M | +$4.8M |
SOPH has burned cash in almost every quarter: −$46M over the past year, against −$44M the year before.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over SOPH on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
SOPH Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.8% | +2.7M shares |
| 1 year | +9.7% | +6.5M shares |
| 3 years | +14% | +9.3M shares |
| 5 years | +17% | +10.5M shares |
| Available history | +92% | +35.5M shares |
SOPH has 74M diluted shares, up 9.7% from a year ago.
| Quarter | Spent |
|---|---|
| Q2 2026 | — |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | — |
| Q3 2024 | — |
SOPH hasn't bought back shares in the past year.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
SOPH Net Leverage
SOPH's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
SOPH Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.8 | Neutral |
| Stochastic | 56.5 | Neutral |
SOPH's weekly RSI is 59 (neutral) and its Stochastic is 57 (neutral).
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
SOPH PE vs Healthcare Sector
SOPH has no meaningful PE right now: it lost money over the past year.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
SOPH Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $7.57 | 3.8% above |
| 20 week MA | $7.25 | 8.4% above |
| 50 week MA | $5.87 | 34% above |
| 100 week MA | $4.68 | 68% above |
| 200 week MA | $4.35 | 81% above |
SOPH has the edge over HIMS on trend strength, trading above more of its moving averages.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.
SOPH Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $16.8 | $13.7 | -19% |
| 2022 | $13.7 | $2.85 | -79% |
| 2023 | $2.85 | $4.71 | +65% |
| 2024 | $4.71 | $3.36 | -29% |
| 2025 | $3.36 | $4.73 | +41% |
| 2026 YTD | $4.73 | $7.86 | +66% |
SOPH has the edge over HIMS on returns for 2026, with the stronger performance.